放疗在进展期霍奇金淋巴瘤中的价值

Value of Radiotherapy in Treating Advanced Stage Hodgkin Lymphoma

下载PDF

导出

摘要 1文献来源 Engert A, Haverkamp H, Kobe C, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin＇ s lymphoma （HD15 trial）： A randomised, open-label, phase 3 non-inferiority trial [ J]. Lancet, 2012,379（9828）： 1791-1799.

作者郭晔蔡绮纯郭汉国

机构地区复旦大学附属肿瘤医院广东省人民医院肿瘤中心

出处《循证医学》 CSCD 2014年第2期77-78,81,共3页 The Journal of Evidence-Based Medicine

关键词霍奇金淋巴瘤化疗放疗 Hodgkin lymphoma chemotherapy radiotherapy

分类号 R733.1 [医药卫生—肿瘤]

引文网络
相关文献

参考文献6

1Fabian C J, Mansfield CM, Dahlberg S, et al. Low-dose involved field radiation after chemotherapy in advanced Hodgkin disease: A Southwest Oncology Group randomized study[J]. Ann Intern Med, 1994,120(11 ) : 903-912.
2Laskar S, Gupta T, Vimal S, et al. Consolidation radiation after complete remission in Hodgkin's disease following six cycles of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine chemotherapy: Is there a need? [Jl. J Clin Oncol, 2004,22(1) : 62-68.
3Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease [J]. N Engl J Med, 2003,348 (24) : 2386-2395.
4Borchmann P, Haverkamp H, Diehl V, et al. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline- dose BEACOPP with or without radiotherapy in patients with advanced-stage Hodgkin's lymphoma: Final analysis of the /-ID12 trial of the German I-Iodgkin Study Group [J]. J Clin Oncol, 2011,29 (32) . 4234-4242.
5Aleman BMP, Raemaekers JMM, Tirelli U, et al. Involved- field radiotherapy for advanced Hodgkin's lymphoma [J]. N Engl J Med, 2003,348 (24) : 2396-2406.
6Engert A, Haverkamp H, Kobe C, et al. Reduced-intensity chemotherapy and PET- guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): A randomised, open-label, phase 3 non-inferiority trial [J]. Lancet, 2012,379(9828) : 1791-1799.

1赵明芳,刘云鹏,娄娜娜.LUX-Lung 6研究引发的EGFR-TKI治疗19 Del和L858R突变晚期非小细胞肺癌疗效探讨[J].循证医学,2015,15(1):37-41. 被引量：2
2范云,张嘉涛.Pembrolizumab联合标准化疗方案治疗晚期非鳞非小细胞肺癌的疗效[J].循证医学,2017,17(1):42-45. 被引量：4
3黄诚,林根,赵宁.化疗和厄洛替尼间插联合疗法在晚期非小细胞肺癌患者的随机对照双盲临床试验[J].循证医学,2014,14(1):41-44.
4周彩存,费世江.有EGFR突变的非小细胞肺癌患者吉非替尼与含铂双药化疗疗效比较[J].循证医学,2011,11(1):28-30. 被引量：3
5林海群,王绍勇,李宝生,翟利民.TRAIL真核表达质粒的构建及其在膀胱癌细胞中的表达[J].山东医药,2008,48(45):13-15.
6陈公琰,杨露璐.一项来自丹麦的低剂量螺旋CT筛查肺癌的前瞻性随机对照研究[J].循证医学,2012,12(4):207-209. 被引量：1
7张天泽,印季良,何友兼,王德元,王怡.PHASE　II　CLINICAL　TRIAL　OF　LASTET　CAPSULE　IN　COMBINATION　CHEMOTHERAPY　OF　MALIGNANT　TUMORSIN　CHINA[J].Chinese Journal of Cancer Research,1995,7(3):181-186.
8赵明芳,何燕燕.吉非替尼初治有效的非小细胞肺癌进展后吉非替尼再治疗的疗效评估[J].循证医学,2013,13(1):43-45. 被引量：1
9郭丽云,马彬,杨克虎,王小虎.放疗联合手术治疗胃癌的Meta分析[J].肿瘤,2010,30(4):303-309. 被引量：5
10邓琳,金冶宁.胃癌术后辅助放化疗的进展和争议[J].外科理论与实践,2008,13(1):79-81.

循证医学

2014年第2期

浏览历史

内容加载中请稍等...

放疗在进展期霍奇金淋巴瘤中的价值

参考文献6

相关作者

相关机构

相关主题

浏览历史